At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 211 enrolled
Drug / intervention
AGEN2034drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating AGEN2034 for Advanced Cancer and Cervical Cancer. Completed, enrolled 211 participants across 44 sites in 9 countries.
Detailed Summary
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer, Cervical Cancer
CountriesAustralia, Belgium, Brazil, Chile, Estonia, France, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartApr 2017
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 7, 2017
Enrollment StartApr 11, 2017
Primary CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 9.2 years ago
Interventions
AGEN2034drug
Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody